Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJ93CT)

Drug Name

Inotersen Drug Info

Synonyms

UNII-0IEO0F56LV; 0IEO0F56LV; Inotersen [USAN]; ISIS 420915

Indication

Disease Entry	ICD 11	Status	REF
Hereditary amyloidosis	5D00.2	Approved	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Transthyretin (TTR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ALN-TTRsc	DMFUOM7	Cardiomyopathy	BC43	Phase 3	[2]
Acoramidis	DMRAP4S	Transthyretin amyloid cardiomyopathy	5D00.20	Phase 3	[3]
NTLA-2001	DM1WDGE	Transthyretin amyloidosis	5D00	Phase 1	[4]
NI006	DM8U8KU	Amyloid transthyretin cardiomyopathy	5D00.20	Phase 1	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
2	Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc.
3	Clinical pipeline report, company report or official report of AstraZeneca
4	CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. N Engl J Med. 2021 Aug 5;385(6):493-502.
5	Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid. N Engl J Med. 2023 Jul 20;389(3):239-250.